- AcelRx Pharmaceuticals (NASDAQ:ACRX) announces that the Anesthetic and Analgesic Drug Products Advisory Committee of the FDA has planned an Advisory Committee meeting to review the Company's NDA for DSUVIA for the management of moderate-to-severe acute pain in medically supervised settings in adult patients.
- The FDA accepted AcelRx's NDA in May. The target action date is November 3.
AcelRx announces date of FDA advisory committee meeting for DSUVIA
Recommended For You
About TLPH Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
TLPH | - | - |
Talphera, Inc. |